Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Amazon Explores AI Content Marketplace With Media Publishers 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
SAN DIEGO, Feb. 21, 2018 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2017 financial results will be released on Thursday, March 1, 2018 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, March 1, 2018, at 4:30 p.m. Eastern Time to discuss the financial results and its plans for addressing the Vitaros Complete Response with the FDA.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 3687726. The live audio webcast can be accessed via the Investor Relations’ section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates: Vitaros, a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan); and RayVa, a product candidate which has completed a Phase 2a clinical trial for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck
[email protected]
The Trout Group LLC
(646) 378-2933
